TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03966248

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chinese Tuina therapy
Description: 1. The doctor presses the affected lower limb from the anterior superior iliac spine to the ankle;~2. The doctor gives the pressure on the Biguan(ST31), Futu(ST32), Heding(EX-LE2), Neixiyan(EX-LE4), Waixiyan(Dubi, ST35), Zusanli(ST36) and Sanyinjiao(SP6) of the affected lower limb;~3. Massage the spleen and stomach meridians of the affected lower extremes;~4. Roll the soft tissues around the affected knee;~5. Relax the gastrocnalis muscle~6. The doctor gives the pressure on the Xuehai(SP10), Liangqiu(ST34), Neixifeng(medial patellofemoral ligament), Waixifeng(lateral patellofemoral ligament), Neixiyan(EX-LE4) and Waixiyan(Dubi, ST35) at the same time;~7. Push the patella and do the passive movement of the affected knee;~8. Strength training of the affected knee.~This group receives 8 treatments over a 3 week period with a one week follow-up on site and a 3 month follow-up by mail, phone or email.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Manual therapy
Description: 1. Manual therapy: Stretching the knee joint, stretching the knee joint with valgus or abduction, stretching the knee joint with varus or adduction is suitable for patients with knee flexion and extension difficulty.Patellar manipulation by bending the knee 5-10 degrees downward is suitable for patients with patellar sliding difficulty.The lower end of the muscle length manipulation is suitable for patients with muscle tension and soft tissue tension.Soft tissue loosening is performed in the suprapatellar and peripatellar regions, medial and lateral capsule joints, and popliteal fossa.~2. Activity training: Mainly about the knee joint flexion and extension movement training.~3. Strength training: Mainly about quadriceps muscle resistance exercises~This group receives 8 treatments over a 3 week period with a one week follow-up on site and a 3 month follow-up by mail, phone or email.
Study: NCT05129436

Intervention type: DRUG
Intervention: Vaxigrip Tetra 2020/2021
Description: vaccine against seasonal influenza
Study: NCT00846521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acarbose
Description: At baseline, subjects underwent an OGTT and 72 hr of out-patient continuous glucose monitoring. They were treated with acarbose (50 mg with meals three times daily) for 6 weeks and repeat 72 hr CGMS profiles were obtained at the end of the study.
Study: NCT00333879

Intervention type: DEVICE
Group type: OTHER
Intervention: Virtual Sound System
Description: Virtual Sound System is tested for efficacy in its ability to realistically simulate Street Crossings sounds in a safe indoor environment. If efficacious, Blind students will be able to practice crossing streets in safety indoors.
Study: NCT01365117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technosphere® Insulin Inhalation Powder
Description: 15 subjects in a three-way crossover (three different doses of TI Inhalation Powder \[one 20 U, two 20 U and one 40 U cartridges)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technosphere® Insulin Inhalation Powder
Description: 16 subjects in a four-way crossover (four different doses of TI Inhalation Powder \[one 20 U, one 20 U plus one 10U, one 30 U (3 U per mg), one 30 U (4 U per mg cartridges)\])
Study: NCT02756026

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multiple micronutrient supplement (Nutri-Fem)
Description: Multiple micronutrient supplement (Nutri-Fem) manufactured by Thorne, containing the Recommended Dietary Intake (RDA).
Study: NCT03899311

Intervention type: OTHER
Intervention: protein-sparing modified fast diet
Description: a PSMF diet follow the usual care format in the Center
Study: NCT02747862

Intervention type: OTHER
Intervention: Chart Review
Description: Database queried for the presence of cases meeting criteria (attenuated FAP, classical AFP \[i.e. identifiable APC mutation\], and/or a compatible family history or personal adenoma burden of \> 50 adenomas).~The data related to the patients with attenuated FAP and classical AFP who underwent endoscopic surveillance or surgery collected through chart review and all data is retrospective as of February 15, 2016.

Intervention type: OTHER
Intervention: Chart Review
Description: Database queried for the presence of cases meeting criteria (attenuated FAP, classical AFP \[i.e. identifiable APC mutation\], and/or a compatible family history or personal adenoma burden of \> 50 adenomas).~The data related to the patients with attenuated FAP and classical AFP who underwent endoscopic surveillance or surgery collected through chart review and all data is retrospective as of February 15, 2016.
Study: NCT01246011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Argatroban and warfarin
Description: Subjects with the presence of heparin PF4 antibodies without signs or symptoms of HIT post CABG will be randomized to receive argatroban and warfarin or no drug for one month.
Study: NCT02550730

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Birth Sisters Best Beginnings for Babies
Description: Birth Sisters Best Beginnings for Babies support during Pregnancy, Labor and Delivery and six weeks postpartum. Participants assigned to the Birth Sister group receive community doula services with consultation from the Medical Legal Partnership when indicated beginning at 24 weeks. Participants receive up to 8 two-hour prenatal home visits; continuous support through labor and birth, and up to 4 two-hour postpartum home visits through 6-8 weeks postpartum.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual maternity care
Description: Usual prenatal, intrapartum and postpartum maternity care
Study: NCT03903926

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 5000 volunteers (6-35 months)-EV71 vaccine
Description: two doses EV71 vaccines will be administrated on day 0, 30 respectively
Study: NCT03199430

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Epigallocatechin gallate

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1450mg Corn Flour
Study: NCT01301586

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline and S-equol
Description: Oral doxycycline and s-equol twice a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Description: ORAL DOXYCYCLINE TWICE A DAY
Study: NCT04498234

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasound guided erector spinae plane block with bupivacaine 0.25% And ultrasound guided Paraveretebral block with bupivacaine 0.25 %
Description: One groupvwill receive 0.25% bupivacaine (20 ml ) into interfascial plane below erector spinae muscle at level of T4 and the other group willreceive (0.3 ml /kg ) 0.25% bubivicaine divided equially at each level of T2 , T4 and T6 at thoracic paravertebral space .
Study: NCT02897687

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facebook Group
Description: A closed, invite-only group within Facebook facilitated by an interprofessional team that not only reinforces skills, but also aims to promote bonds and a sense of community and connectedness between participants.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Book Club Group
Description: A topical book club group discussing Autism-related material conducted by a single healthcare professional.
Study: NCT02345616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric oxide
Study: NCT03072992

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo i.v. solution, once weekly for 12 weeks
Study: NCT00003834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Study: NCT00468052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: 2 micrograms/kilogram as a bolus then 0.7 micrograms/kilogram infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fentanyl
Description: 1 microgram/kilogram as a bolus
Study: NCT01864889

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-CD19-CAR vector-transduced T cells
Description: genetically engineered lymphocyte therapy
Study: NCT03918967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT-G11
Description: oral tablet of CT-G11 Experimental Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT-G20
Description: oral tablet of CT-G20 Experimental Drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CT-G11 Placebo
Description: oral tablet of Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CT-G20 Placebo
Description: oral tablet of Placebo
Study: NCT03991754

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transcatheter aortic valve implantation
Description: transcatheter aortic valve implantation

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: transcatheter aortic valve implantation
Description: transcatheter aortic valve implantation
Study: NCT02530216

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AEGIS (Automated Evaluation of Gastrointestinal Symptoms)
Description: AEGIS (Automated Evaluation of Gastrointestinal Symptoms) guides patients through questionnaires to measure symptom attributes including the timing, severity, frequency, location, quality, and character of their gastrointestinal (GI) symptoms, along with relevant comorbidities, family history, and alarm features. This information is transformed into a history of present illness (HPI) written in language familiar to clinicians. AEGIS also supports both the clinician and patient with an individualized education prescription which guides the patient through a library of multi-media educational materials on GI symptoms, conditions, and treatments. The prescription is created by the portal based on each patient's unique AEGIS fingerprint.
Study: NCT03258268

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard of Care with EASY DSS
Description: The EASY DSS is a software tool designed to process and analyze data to facilitate individualized treatment suggestions for type 2 diabetes patients.~Patients will receive standard of care with a board certified physician with EASY DSS.~The choice of treatment will be made by the investigator. In the investigational arm this will be based on the clinical judgment of the investigator supplemented with support from the EASY DSS and in the control arm this will be based on the clinical judgment of the investigator alone.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care without EASY DSS
Description: Patients will receive standard of care with a board certified physician without EASY DSS.~The choice of treatment will be made by the investigator. In the investigational arm this will be based on the clinical judgment of the investigator supplemented with support from the EASY DSS and in the control arm this will be based on the clinical judgment of the investigator alone.
Study: NCT05464043

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: evaluation of second line glucose homeostasis
Description: blood samples, urine samples, genetic test, peptide C stimulation test, OGTT, continuous glucose monitoring and questionnaires
Study: NCT00405886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neramexane
Description: Oral tablets, duration: 16 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neramexane
Description: Oral tablets, duration: 16 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neramexane
Description: Oral tablets, duration: 16 weeks
Study: NCT04476810

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: kahook dual blade
Description: Combined Phacoemulsification and Excisional Goniotomy with the Kahook Dual Blade
Study: NCT03272087

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracoscopy
Description: 50 % of patients will have performed af medical thoracoscopy (pleuroscopy)
Study: NCT00405886

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablets, duration: 16 weeks
Study: NCT03449927

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Specialized menu
Description: -Specialized menu that will guide participant food choices if the participant experiences nausea or diarrhea

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care menu
Description: -Standard registered dietitian support

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self report dietary intake worksheet
Description: -Self report nausea and diarrhea

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self report dietary intake worksheet
Description: -Self report nausea and diarrhea

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Post study questionnaire
Description: -Completed upon count recovery and prior to discharge

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post study questionnaire
Description: -Completed upon count recovery and prior to discharge
Study: NCT01783249

Intervention type: OTHER
Group type: OTHER
Intervention: Stationary Exercise cycling
Description: Stationary exercise cycling
Study: NCT02605356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radium-223 dichloride (Xofigo, BAY88-8223)
Study: NCT05247385

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasugrel
Description: Compared platelet inhibition and adenosine levels at baseline and after 15 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasugrel
Description: Compared platelet inhibition and adenosine levels at baseline and after 15 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: Compared platelet inhibition and adenosine levels at baseline and after 15 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: Compared platelet inhibition and adenosine levels at baseline and after 15 days
Study: NCT04804865

Intervention type: OTHER
Intervention: prognostic assessment
Description: determination of a prognostic score with 3 clinical and 5 biological parameters.
Study: NCT03382314

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: HDDO-1614
Description: * Combination drug (Bazedoxifene + Cholecalciferol)~* Incrementally modified drug~* Not market authorized product

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bazedoxifene / Cholecalciferol
Description: Co- Administration of Bazedoxifene and Cholecalciferol
Study: NCT02788786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Description: non-alcoholic chlorhexidine gluconate antiseptic mouth rinse

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetylpyridinium chloride
Description: non-alcoholic cetylpyridinium chloride antiseptic mouth rinse

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salt and Water
Description: salt and water mix oral rinse
Study: NCT03522610

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ADAPT
Description: Two hour, once a week in-person parenting program for 14 weeks plus use web-enhanced supplemental ADAPT materials
Study: NCT02477163

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ayurveda treatment
Description: 1. Gokshuradi Guggulu (compound Ayurvedic preparation: Gokshura + Guggulu + Triphala + Trikatu + Musta) - 1 g, 3 times in a day after food with warm water.~2. Varunadi kvath (ingredients: Varuna tvak + Bilva moola + Apamarga + Chitrak moola + Arani + Shigru + Bruhati + Kirattikta + Karanja + Shatavari) - 40 ml 2 times in a day after food.~3. Rasayan Churna (powder of Gokshura + Amalaki + Guduchi in equal quantities ) - 3 g, 3 times a day with water.~4. Bhumyamalaki (Tamalaki Rasayan) tablet - 1 g, 2 times in a day after food with water.~5. Uricare (of Punarvasu Pharmacy, Petlad road, Nadiad) tablet - 1 g, 3 times in a day after food with warm water.~6. Niruha Basti (procto-colonic administration of ayurvedic medicine) with Punarnavadi kvath (decoction) - in the morning, before one hour of the lunch.
Study: NCT04841460

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low-fat ground beef
Description: 5% fat ground beef

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High-fat ground beef
Description: 25% fat ground beef
Study: NCT03441724

Intervention type: DIAGNOSTIC_TEST
Intervention: Mechanocardiography
Description: Mechanocardiographic recording

Intervention type: DIAGNOSTIC_TEST
Intervention: Mechanocardiography
Description: Mechanocardiographic recording
Study: NCT02369900

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esmolol
Study: NCT01201005

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxycobalamin
Description: Hydroxycobalamin 400 µg (Vitamin B12 depot, Nycomed Pharma ) is given as a single intramuscular injection

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Sham injection
Description: needle injection without any substance given
Study: NCT04561830

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic-assited excision of mesorectum with pelvic lymph nodes excision
Description: We performed laparoscopic dissection of the lateral pelvic lymph node for thirty patients while we performed open lateral pelvic lymph node dissection for the remaining thirty patients.~Performed surgical approaches were abdominoperineal resection, internal sphincter resection, and low anterior resection. All performed surgical procedures included lateral pelvic lymphadenectomy in addition to performing total mesorectal excision.~Choosing whether to perform unilateral or bilateral lymphadenectomy depends on lymph nodes invasion by cancer was on one side or both sides.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic-assited excision of mesorectum with pelvic lymph nodes excision
Description: We performed laparoscopic dissection of the lateral pelvic lymph node for thirty patients while we performed open lateral pelvic lymph node dissection for the remaining thirty patients.~Performed surgical approaches were abdominoperineal resection, internal sphincter resection, and low anterior resection. All performed surgical procedures included lateral pelvic lymphadenectomy in addition to performing total mesorectal excision.~Choosing whether to perform unilateral or bilateral lymphadenectomy depends on lymph nodes invasion by cancer was on one side or both sides.
Study: NCT02313792

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Palifermin
Study: NCT01190345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Patients receive on day 1 of each cycle : bevacizumab 15 mg/kg (8 injections in total).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: no bevacizumab
Description: no bevacizumab
Study: NCT04729868

Intervention type: DRUG
Group type: OTHER
Intervention: Levobupivacaine(chirocaine) plus dexmedetomidine(precedex)
Description: evaluate the efficacy of levo-bupivacaine alone and with dexmedetomidine in Ultrasound guided infraclavicular brachial plexus block for hand and forearm surgeries

Intervention type: DRUG
Group type: OTHER
Intervention: Levobupivacaine(chirocaine) plus dexmedetomidine(precedex)
Description: evaluate the efficacy of levo-bupivacaine alone and with dexmedetomidine in Ultrasound guided infraclavicular brachial plexus block for hand and forearm surgeries

Intervention type: DRUG
Group type: OTHER
Intervention: Levobupivacaine(chirocaine) plus dexmedetomidine(precedex)
Description: evaluate the efficacy of levo-bupivacaine alone and with dexmedetomidine in Ultrasound guided infraclavicular brachial plexus block for hand and forearm surgeries
Study: NCT02369900

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Study: NCT02207244

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: 80 mg by subcutaneous injection at Week 0, then 40 mg at Week 1 and every 2 weeks (q2w) thereafter through Week 23.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for adalimumab
Description: Placebo for adalimumab \[two 0.8 milliliter (mL) injections\] at week 0 followed by one 0.8 mL injection at weeks 1, 3, 5, and every 2 week (q2w) through Week 23 (Group I and II).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for adalimumab
Description: Placebo for adalimumab \[two 0.8 milliliter (mL) injections\] at week 0 followed by one 0.8 mL injection at weeks 1, 3, 5, and every 2 week (q2w) through Week 23 (Group I and II).
Study: NCT01925937

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Study: NCT02424006

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RHCIII-MPC cornea
Description: Patients will undergo surgery using conventional anterior lamellar keratoplasty technique: diseased cornea will be trephined to 350 um of corneal thickness and then a lamellar dissection will be created. Trephine diameter will be 7.5 mm. Alternatively a femtosecond laser may be used to create the dissection. A RHCIII-MPC cornea 350 um thick and equal or 0.25 mm larger diameter is placed and sutured. The sutures are superimposed and the implant and the sutures covered with a bandage contact lens. The sutures and bandage lens will be removed later after the initial healing period of 4 weeks or as determined by physician depending on the implant epithelial coverage.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Donor cornea
Description: Patients will undergo surgery using conventional anterior lamellar keratoplasty technique: diseased cornea will be trephined to 350 um of corneal thickness and then a lamellar dissection will be created. Trephine diameter will be 7.5 mm. Alternatively a femtosecond laser may be used to create the dissection. A human donor cornea graft 350 um thick and 0.25 mm larger diameter is placed and sutured. The sutures will be removed in 3-6 months or as determined by physician.
Study: NCT04700436

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuzet tablet 10/5 mg (Ezetimibe 10 mg/Rosuvastatin 5 mg)
Description: IP~* Test drug: Rosuzet tablet 10/5 mg (Ezetimibe 10 mg/Rosuvastatin 5 mg)~* Control drug: Suvast tablet 10 mg (Rosuvastatin 10 mg)
Study: NCT01925937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo for coenzyme Q10
Study: NCT02131207

Intervention type: DEVICE
Intervention: magnetic resonance imaging
Description: Undergo pelvic MRI
Study: NCT04700436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuzet tablet 10/5 mg (Ezetimibe 10 mg/Rosuvastatin 5 mg)
Description: IP~* Test drug: Rosuzet tablet 10/5 mg (Ezetimibe 10 mg/Rosuvastatin 5 mg)~* Control drug: Suvast tablet 10 mg (Rosuvastatin 10 mg)
Study: NCT02035579

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Training Intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stretching Intervention
Study: NCT04507776

Intervention type: DRUG
Intervention: Etanercept
Description: Patients with spondyloarthrosis as provided in real world practice